LAMP2 and hematopoietic and lymphoid system neoplasm: In addition, we validated the prognostic value of LAMP2 in a variety of cancers including LUAD, GBMLGG, breast cancer, colorectal cancer, blood cancer (follicular lymphoma), and soft tissue cancer (liposarcoma) using PrognoScan based on the GEO dataset (Supplementary Table 1).